Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GSK plc
  6. News
  7. Summary
    GSK   GB00BN7SWP63

GSK PLC

(GSK)
  Report
Delayed London Stock Exchange  -  11:35 2022-12-02 am EST
1424.00 GBX   +0.61%
12/02ADRs End Mostly Higher, H World and RedHill BioPharma Trade Actively
DJ
12/02Plunging Eurozone Industrial Producer Prices Push European Equities Lower
MT
12/02Jemperli (dostarlimab) RUBY phase III trial met its primary endpoint in a planned interim analysis in patients with primary advanced or recurrent endometrial cancer
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GSK : JP Morgan sticks Neutral

10/04/2022 | 03:05am EST

Analyst James Gordon from JP Morgan research gives the stock a Neutral rating. The target price is unchanged and still at GBX 1900.


ę MarketScreener with dpa-AFX Analyser 2022
All news about GSK PLC
12/02ADRs End Mostly Higher, H World and RedHill BioPharma Trade Actively
DJ
12/02Plunging Eurozone Industrial Producer Prices Push European Equities Lower
MT
12/02Jemperli (dostarlimab) RUBY phase III trial met its primary endpoint in a planned inter..
AQ
12/02AnaptysBio: Trial of Jemperli Drug Meets Primary Endpoint
DJ
12/02Is the job report good or bad news?
MS
12/02GSK Says Cancer Drug Met Primary Endpoint in Interim Analysis of Phase 3 Trial
MT
12/02GSK Says European Medicines Agency Accepted Marketing Authorization Application for Pot..
MT
12/02Gsk : European Medicines Agency accepts marketing authorisation application for momelotini..
PU
12/02Analyst recommendations: Blackstone, BT Group, Ecolab, GSK, Sain..
MS
12/02Citigroup Cuts GSK PT, Keeps Neutral Rating
MT
More news
Analyst Recommendations on GSK PLC
More recommendations
Financials
Sales 2022 29 184 M 35 748 M 35 748 M
Net income 2022 4 324 M 5 297 M 5 297 M
Net Debt 2022 14 343 M 17 570 M 17 570 M
P/E ratio 2022 12,7x
Yield 2022 4,23%
Capitalization 57 447 M 70 368 M 70 368 M
EV / Sales 2022 2,46x
EV / Sales 2023 2,36x
Nbr of Employees 90 096
Free-Float 93,7%
Chart GSK PLC
Duration : Period :
GSK plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GSK PLC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 1 424,00 GBX
Average target price 1 709,73 GBX
Spread / Average Target 20,1%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Jon Ellis VP & Head-Technology Business Development
Tony Wood Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GSK PLC-13.36%70 368
JOHNSON & JOHNSON4.57%467 679
ELI LILLY AND COMPANY34.07%356 089
ABBVIE INC.20.87%289 331
NOVO NORDISK A/S22.04%285 887
PFIZER, INC.-13.50%285 774